CTUK vs. BIOG, AIE, LWI, CTPE, SST, GSF, HNE, BIPS, HINT, and JAGI
Should you be buying CT UK Capital and Income stock or one of its competitors? The main competitors of CT UK Capital and Income include Biotech Growth (BIOG), Ashoka India Equity Investment (AIE), Lowland (LWI), CT Private Equity Trust (CTPE), The Scottish Oriental Smaller Companies Trust (SST), Gore Street Energy Storage Fund (GSF), Henderson EuroTrust (HNE), Invesco Bond Income Plus (BIPS), Henderson International Income (HINT), and JPMorgan Asia Growth & Income (JAGI). These companies are all part of the "asset management" industry.
The Biotech Growth Trust (LON:BIOG) and CT UK Capital and Income (LON:CTUK) are both small-cap financial services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
In the previous week, The Biotech Growth Trust had 1 more articles in the media than CT UK Capital and Income. MarketBeat recorded 1 mentions for The Biotech Growth Trust and 0 mentions for CT UK Capital and Income. CT UK Capital and Income's average media sentiment score of 1.79 beat The Biotech Growth Trust's score of 0.00 indicating that The Biotech Growth Trust is being referred to more favorably in the media.
The Biotech Growth Trust has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, CT UK Capital and Income has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
The Biotech Growth Trust's return on equity of -1.08% beat CT UK Capital and Income's return on equity.
The Biotech Growth Trust received 82 more outperform votes than CT UK Capital and Income when rated by MarketBeat users.
26.7% of The Biotech Growth Trust shares are held by institutional investors. Comparatively, 83.4% of CT UK Capital and Income shares are held by institutional investors. 0.5% of The Biotech Growth Trust shares are held by insiders. Comparatively, 0.4% of CT UK Capital and Income shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
CT UK Capital and Income has higher revenue and earnings than The Biotech Growth Trust. CT UK Capital and Income is trading at a lower price-to-earnings ratio than The Biotech Growth Trust, indicating that it is currently the more affordable of the two stocks.
Summary
CT UK Capital and Income beats The Biotech Growth Trust on 7 of the 13 factors compared between the two stocks.
Get CT UK Capital and Income News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTUK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTUK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CT UK Capital and Income Competitors List
Related Companies and Tools
